Biocon Limited — Q3 FY25
Biocon's Q3 FY25 results were in line with expectations, with consolidated revenue from operations of INR 3,821 crore, up 10% YoY on a like-for-like basis.
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
54%Questions answered4Evaded / deflected12Questions auditedContradictedNumbers vs filing
Evasive
High priority
What is the expected uptake for Stelara biosimilar launch?
Asked by Damayanti Kerai, HSBC
Management expressed excitement but gave no concrete feedback from channel partners or quantitative uptake expectations.
no specific uptake guidancegeneric optimism
Read the exchange
Question
So, just want to understand, based on your discussion with channel partners, what kind of sense you are getting for potential uptake of this product?
Shreehas Tambe, CEO and MD, Biocon Biologics Limited
We will be amongst that wave of products that will be coming to the United States. ... Our teams are working very hard with customers, both commercial as well as the government customers as well. And we believe we will be very competitive in this space.
Partial answer
High priority
Why is profitability not matching revenue growth in existing biosimilars?
Asked by Damayanti Kerai, HSBC
Management denied low-margin channel shift but did not explain the profitability gap with specific numbers.
no specific margin breakdown by channel
Read the exchange
Question
However, when we look at the profitability side, it's not in line with, I think, the kind of pickup seen on the revenue side. So, can you just comment whether most of the market share gain is on low realization channels?
Shreehas Tambe, CEO and MD, Biocon Biologics Limited
I wouldn't say that it's a low margin business... growth has come because of the large increase in market share... That growth has not necessarily come in from low margin business.
Answered
Medium priority
What will be Biocon's diluted holding in BBL after buying 1.5% stake?
Asked by Neha Manpuria, Bank of America
Management provided specific updated holding percentage after the stake purchase.
Read the exchange
Question
Just wanted to understand what would be our diluted holding, fully diluted holding in BBL after this deal. I think the last number was about 70%.
Siddharth Mittal, CEO and MD, Biocon Limited
We were closer to a little over 71%, so. ... I think we'll get closer to 73%-74% after the acquisition.
Answered
High priority
What is the net debt after the short-term bridging loan?
Asked by Neha Manpuria, Bank of America
Management gave specific net debt figures for BBL and consolidated level.
Read the exchange
Question
And what would be our net debt post the short-term bridging loan to fund this stake purchase at the consolidated level?
Siddharth Mittal, CEO and MD, Biocon Limited
At Biocon Biologics, it's roughly $1.25 billion. This is now December. So, you'll add another $65 million of the commercial papers, so that'll get you to $1.3 billion.
Answered
High priority
When will generics business return to mid-teens growth?
Asked by Neha Manpuria, Bank of America
Management confirmed mid-teens growth expected in FY26.
Read the exchange
Question
But if I remember, at one point, we guided to this business probably growing 15%, mid-teens sort of growth at some point. One, what takes us there? When do we get there?
Siddharth Mittal, CEO and MD, Biocon Limited
Fiscal 2026 itself, you'll start seeing fiscal.
Answered
High priority
What is pending from FDA for Bevacizumab and Aspart approvals?
Asked by Neha Manpuria, Bank of America
Management clearly stated the remaining issue (GMP status) and current actions.
Read the exchange
Question
Is there anything else that is pending from the U.S. FDA? Have we heard anything on the Aspart filing? Is there anything else pending for us to get approval for those two products?
Shreehas Tambe, CEO and MD, Biocon Biologics Limited
The only piece that was remaining was the site GMP status. With that achieved, we've responded to them... and our regulatory team is in conversation with them to see how we can move this in an expedited manner.
Partial answer
High priority
Why hasn't revenue grown proportionally to market share gains?
Asked by Shyam Srinivasan, Goldman Sachs
Management acknowledged price erosion but did not quantify it, citing product-by-product variation.
no specific price erosion percentage
Read the exchange
Question
Most of our market shares for our commercial molecules in the US have actually doubled... So, I just want to understand, has there been price erosion? What is the delta on our volume?
Shreehas Tambe, CEO and MD, Biocon Biologics Limited
The market share growth reflects a volume growth... Now, whether that increased volume directly reflects in increased revenues as a proportional thing is not an expectation because as you look at how markets evolve, not every product will retain the value that it has a year ago.
Evasive
High priority
What is the capital allocation strategy and debt reduction plan?
Asked by Shyam Srinivasan, Goldman Sachs
Management gave no concrete plan or timeline for debt reduction, only general commitment.
no specific debt reduction timelinevague commitment
Read the exchange
Question
So, just from an overall capital allocation, can you walk us through what's happening? ... And our measures to reduce net debt, right? So, it seems to be going up, not down.
Peter Bains, CEO, Biocon Group
We will continue to balance meeting the obligations that we have... But we are committed to and will continue to look to pare down debt as we move forward. But it's not a straight line.
Declined
High priority
What other liquidity options exist for investors and what is the near-term liability?
Asked by Love Sharma, JPMorgan
Management declined to provide specifics on other liquidity options or amounts.
refused to share details
Read the exchange
Question
Could you elaborate what kind of other such options are still available with those investors? And what could we expect in the near term?
Peter Bains, CEO, Biocon Group
We have a number of investors. We're working with all of them. ... I think it would be inappropriate to go into details individually here.
Answered
Medium priority
What amount was settled with Viatris in December quarter?
Asked by Love Sharma, JPMorgan
Management provided the exact amount settled in the quarter.
Read the exchange
Question
I think on the Viatris full and final settlement, could you share what is the amount which has been settled there in December quarter?
Shreehas Tambe, CEO and MD, Biocon Biologics Limited
And now we have closed the remaining $160 million. So, with this now, there is a full and final settlement and closure of all transactions that was related to the Viatris acquisition.
Partial answer
High priority
Are margin guidance of 20-23% conservative given new launches?
Asked by Vivek Agarwal, Citibank
Management acknowledged potential upside but did not revise the 20-23% range, leaving it open-ended.
no revised margin guidancekept range open
Read the exchange
Question
So, I was surprised that given that you have cleared the facilities, expected to launch some of the new products... is it not a conservative guidance, or should we expect the margins to move up substantially?
Shreehas Tambe, CEO and MD, Biocon Biologics Limited
We certainly have a lot of things moving in the right direction... The year ahead, we have five new launches coming up in the U.S. and three globally, so certainly, whenever you have a new product launch, you will see a slightly better than expected performance.
Evasive
High priority
What is the long-term growth trajectory for biosimilar business?
Asked by Bharat Sheth, Quest Investment Advisors
Management declined to give any quantitative growth trajectory, citing no specific guidance.
no specific growth guidancevague optimism
Read the exchange
Question
So, how do I mean, we have to give a little longer-term trajectory for our biosimilar business. So, how do we see that business growth?
Shreehas Tambe, CEO and MD, Biocon Biologics Limited
While I do not want to provide specific guidance, we believe the future will also be predictably positive as we look to bring more products into the market.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| BBL EBITDA margin sustainable at 22%-23% | 22.5% | 20% | Overstated vs filing |
| Generics EBITDA margin guidance 10%-12% | 11% | 20% | Understated vs filing |
| Generics EBITDA margin to reach 13%-14% in 1-2 years | 13.5% | 20% | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.